SCHEMBL6375117

SCHEMBL6375117

O=c1ncc2cncn2c2ccccc12

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GABRA5 P31644 10/20 0.41
CYP11B2 P19099 1/20 0.39
KDM4C Q9H3R0 1/20 0.38
GABRA1 P14867 7/20 0.37
TDO2 P48775 1/20 0.36
CHEK1 O14757 1/20 0.36
CHEK2 O96017 1/20 0.36
CDK1 P06493 1/20 0.36
GSK3B P49841 1/20 0.36
PRKDC P78527 1/20 0.36
KDM4E B2RXH2 2/20 0.34
HPGD P15428 2/20 0.34
HSD17B10 Q99714 2/20 0.34
ALDH1A1 P00352 2/20 0.34
GLA P06280 1/20 0.34
GAA P10253 1/20 0.34
BRD9 Q9H8M2 1/20 0.34
IDO1 P14902 1/20 0.33
TBXAS1 P24557 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29742732 0.75 KDM4E (0.59) KDM4EHPGDHSD17B10ALDH1A1GLA
SCHEMBL970053 0.75 KDM4E (0.59) KDM4EHPGDHSD17B10ALDH1A1GLA
SCHEMBL11265444 0.71 GABRA5 (0.50) GABRA5GABRA1CHEK1CHEK2CDK1
SCHEMBL11265442 0.70 KDM4E (0.44) CHEK1KDM4EHPGDHSD17B10ALDH1A1
SCHEMBL10681757 0.69 GABRA5 (0.36) GABRA5GABRA1KDM4EHPGDHSD17B10
SCHEMBL3356849 0.69 GABRA5 (0.50) GABRA5GABRA1TDO2IDO1
SCHEMBL5995444 0.67 KDM4E (0.53) GABRA5GABRA1KDM4EHPGDHSD17B10
SCHEMBL10514072 0.67 HTT (0.56) ALDH1A1
SCHEMBL5274622 0.67 NQO2 (0.41) KDM4CKDM4EHPGDHSD17B10ALDH1A1
SCHEMBL31515495 0.67 PARP1 (0.48) GABRA5CHEK1CHEK2CDK1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009733-A1 Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage PHARMACIA CORPORATION 2005-01-13 US disclosed
EP-0285837-A1 Imidazodiazepin derivatives F. HOFFMANN-LA ROCHE AG (CH) 1988-10-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009733-A1 Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage KCNJ2, KCNN2, KCNK2 GABRA5 787/4885CYP11B2 1003/4885KDM4C 2062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.